AR104361A1 - Terapia de combinación de anticuerpo que se une a angiopoyetina 2 con anticuerpo que se une al ligando 1 de muerte programada - Google Patents

Terapia de combinación de anticuerpo que se une a angiopoyetina 2 con anticuerpo que se une al ligando 1 de muerte programada

Info

Publication number
AR104361A1
AR104361A1 ARP160101127A ARP160101127A AR104361A1 AR 104361 A1 AR104361 A1 AR 104361A1 AR P160101127 A ARP160101127 A AR P160101127A AR P160101127 A ARP160101127 A AR P160101127A AR 104361 A1 AR104361 A1 AR 104361A1
Authority
AR
Argentina
Prior art keywords
antibody
joins
combination therapy
binds
angiopoyetina
Prior art date
Application number
ARP160101127A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR104361A1 publication Critical patent/AR104361A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

Reivindicación 1: Un anticuerpo que se une a angiopoyetina 2 (ANG-2), en el que el anticuerpo se administra en una terapia de combinación con un anticuerpo que se une a PD-L1, para su uso en a) tratar el cáncer, b) retrasar la progresión del cáncer, c) prolongar la supervivencia de un paciente que padece cáncer, o d) estimular una respuesta inmunitaria mediada por células. Reivindicación 16: Una composición farmacéutica, que comprende un anticuerpo que se une a ANG-2, y un anticuerpo que se une a PD-L1, en el que cada anticuerpo se formula junto con un vehículo farmacéuticamente aceptable.
ARP160101127A 2015-04-23 2016-04-22 Terapia de combinación de anticuerpo que se une a angiopoyetina 2 con anticuerpo que se une al ligando 1 de muerte programada AR104361A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15164803 2015-04-23

Publications (1)

Publication Number Publication Date
AR104361A1 true AR104361A1 (es) 2017-07-12

Family

ID=52997970

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160101127A AR104361A1 (es) 2015-04-23 2016-04-22 Terapia de combinación de anticuerpo que se une a angiopoyetina 2 con anticuerpo que se une al ligando 1 de muerte programada

Country Status (7)

Country Link
US (1) US20180155431A1 (es)
EP (1) EP3286217A1 (es)
JP (1) JP2018515450A (es)
CN (1) CN107406502A (es)
AR (1) AR104361A1 (es)
HK (1) HK1247217A1 (es)
WO (1) WO2016170040A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
IL292449B2 (en) 2015-03-13 2024-02-01 Cytomx Therapeutics Inc Nucleic acids encoding antibodies against PDL1 and methods for their preparation
RU2744860C2 (ru) 2015-12-30 2021-03-16 Кодиак Сайенсиз Инк. Антитела и их конъюгаты
KR20180097615A (ko) 2016-01-08 2018-08-31 에프. 호프만-라 로슈 아게 Pd-1 축 결합 길항물질 및 항-cea/항-cd3 이중특이성 항체를 사용하는 cea-양성 암의 치료 방법
KR20200016899A (ko) 2017-06-01 2020-02-17 싸이톰스 테라퓨틱스, 인크. 활성화가능 항-pdl1 항체, 및 이의 이용 방법
KR20200013231A (ko) 2017-06-02 2020-02-06 베링거 인겔하임 인터내셔날 게엠베하 항암 조합 요법
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG196798A1 (en) * 2008-12-09 2014-02-13 Genentech Inc Anti-pd-l1 antibodies and their use to enhance t-cell function
TWI426920B (zh) * 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
ES2742379T3 (es) * 2012-05-31 2020-02-14 Hoffmann La Roche Procedimientos de tratamiento del cáncer usando antagonistas de unión al eje de PD-1 y antagonistas de VEGF

Also Published As

Publication number Publication date
CN107406502A (zh) 2017-11-28
HK1247217A1 (zh) 2018-09-21
US20180155431A1 (en) 2018-06-07
EP3286217A1 (en) 2018-02-28
JP2018515450A (ja) 2018-06-14
WO2016170040A1 (en) 2016-10-27

Similar Documents

Publication Publication Date Title
AR104361A1 (es) Terapia de combinación de anticuerpo que se une a angiopoyetina 2 con anticuerpo que se une al ligando 1 de muerte programada
BR112018068748A2 (pt) composto, composição farmacêutica e de vacina, métodos para indução ou promoção de uma resposta imunológica, para tratamento de câncer, de doenças infecciosas, de distúrbios imunológicos e de doenças imunológicas e para tratamento ou prevenção de uma doença, e, uso de um composto
MX2019012233A (es) Anticuerpos anti-sirpa.
EA201891186A1 (ru) Антитела, нейтрализующие вирус иммунодефицита человека
CL2015000784A1 (es) Compuestos derivados de acilaminopirimidina, inductores de interferon; composicion farmaceutica que los comprende; su uso en el tratamiento de infecciones viricas, trastornos inmunitarios, cancer y otras enfermedades.
EA201890530A1 (ru) Конъюгаты антитела к dll3 и лекарственного средства и способы их применения
EA201790932A1 (ru) Дозировка и введение нефукозилированных анти-cd40 антител
PH12018500174A1 (en) Combined use of anti pd-1 and anti m-csf antibodies in the treatment of cancer
BR112015019064A2 (pt) métodos de tratamento de melanoma
SV2018005682A (es) Composiciones terapeuticas para el tratamiento del virus de inmunodeficiencia humana
CL2016002794A1 (es) Vacuna de péptido que comprende un péptido ras mutante y un agente quimioterapéutico
CL2016000008A1 (es) Tratamiento de lesiones inflamatorias de rosacea con ivermectina.
MX2017003211A (es) Anticuerpos anti-met y composiciones.
CL2018003608A1 (es) Anticuerpo aislado o fragmento de unión a antígeno del mismo que se une específicamente interleucina-25 hjumana (il-2525); composición farmacéutica que lo comprende; uso de dicha composición farmacéutica para tratar una enfermedad o trastorno asociado con la actividad o expresión de il-25. (divisional solicitud 201700703)
CL2018001722A1 (es) Nuevos anticuerpos anti-mfi2 y métodos de uso (divisional solicitud 201700506)
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
BR112017007817A2 (pt) tratamento do câncer com estimuladores imunológicos
MX2018006996A (es) Composiciones y metodos mejorados para la entrega viral de neoepitopos y usos de estos.
EA201690388A1 (ru) Новые производные унциаламицина, способы их синтеза и их применение в качестве противоопухолевых агентов
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
BR112015031417A2 (pt) forma de dosagem farmacêutica, composição farmacêutica, métodos para tratamento de um paciente com necessidade de cisteamina e para preparo de uma forma de dosagem
MX2020003732A (es) Derivado de anillo fusionado como inhibidor del receptor a2a.
CO2019009000A2 (es) Combinaciones farmacéuticas para tratar cáncer
MX2017014396A (es) Tratamiento de mieloma multiple.
DOP2016000003A (es) Formas de dosificación farmacéuticas estabilizadas que comprenden atrasentán

Legal Events

Date Code Title Description
FB Suspension of granting procedure